RxDoctor Payments DataLook up a doctor →

Syed Rab, MD

Nephrology · Hammond, LANPI 1891751301

Payments from drug & device makers

$10,360in general payments, 2019–2025

Across 603 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • OPKO Pharmaceuticals, LLC$882
  • Akebia Therapeutics Inc$832
  • Calliditas Therapeutics US Inc.$675
  • Vifor Pharma, Inc.$632
  • plus $5K from 32 others

What the payments were for

  • Food & beverage$10,26099%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,360 in reported general payments places this provider in the 80th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$561,242
Medicare patients
688
Services billed
5,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan31$613,230
AuryxiaFerric Citrate237$439,985
RayaldeeCalcifediol92$143,101
VelphoroSucroferric Oxyhydroxide47$129,792
KerendiaFinerenone121$105,488
Cinacalcet Hcl172$59,387
JardianceEmpagliflozin47$35,064
GlyxambiEmpagliflozin/Linagliptin36$33,354
OzempicSemaglutide19$30,118
Sevelamer Carbonate132$29,943
EntrestoSacubitril/Valsartan35$24,739
LokelmaSodium Zirconium Cyclosilicate34$24,418
VeltassaPatiromer Calcium Sorbitex15$20,362
Lanthanum Carbonate22$17,001
MyrbetriqMirabegron26$15,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$1,158$613,23031 claims
Akebia Therapeutics IncAuryxia$832$439,985237 claims
OPKO Pharmaceuticals, LLCRayaldee$882$143,10192 claims
Fresenius USA Marketing, Inc.Velphoro$544$129,79247 claims
BayerKerendia$601$105,488121 claims
Boehringer IngelheimJardiance, Glyxambi$119$68,41883 claims
AstraZenecaLokelma, Farxiga$561$33,77546 claims
Novo NordiskOzempic$174$30,11819 claims
NovartisEntresto$105$24,73935 claims
MerckJanuvia$17$10,27315 claims
Arbor Pharmaceuticals, Inc.Edarbi$46$3,49715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 206 nephrology providers in Louisiana.

Other nephrology in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →